Protein / target
Oxytocin receptor
Protein at a glance
Biological role
Vasopressin receptor
Strongest disease association
Postpartum hemorrhage
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
G protein-coupled receptor for oxytocin (OXT), a neuropeptide hormone released by the posterior pituitary gland that plays a key role in social behavior and other biological processes, such as milk ejection.
View complete UniProt function annotationHide complete annotation
G protein-coupled receptor for oxytocin (OXT), a neuropeptide hormone released by the posterior pituitary gland that plays a key role in social behavior and other biological processes, such as milk ejection (PubMed:11923477, PubMed:22069312, PubMed:32832646, PubMed:35104164, PubMed:35241813, PubMed:35851571). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as phospholipase C (PubMed:22069312, PubMed:32832646, PubMed:35104164, PubMed:35241813, PubMed:35851571). OXTR is mainly coupled to G(q) G proteins and mediates production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca(2+) ions from intracellular stores, respectively (PubMed:11923477, PubMed:22069312, PubMed:32832646, PubMed:35104164, PubMed:35241813, PubMed:35851571). In presence of high levels of oxytocin, also coupled to G(i) G proteins, mediating inhibition of adenylate cyclase activity (PubMed:22069312, PubMed:35241813, PubMed:35851571). Central release of oxytocin plays essential roles in social behavior, such as maternal care, social cognition and affiliative behaviors, triggering signaling that modulates neural circuits by altering ion channel activity, changing intrinsic neuronal properties and modifying synaptic transmission (both excitatory and inhibitory) (PubMed:19934046, PubMed:20647384, PubMed:21896752, PubMed:22123970, PubMed:24367110). Peripheral release of oxytocin (secretion into the bloodstream) promotes various processes, such as parturition, lactation or osteoblast differentiation (PubMed:6278592). OXTR-mediated signaling promotes milk ejection by triggering and strengthening contraction of the smooth muscle of mammary gland (By similarity)
Subcellular location
Domains and Gene Ontology detail (13)Hide
Gene Ontology
- Cplasma membrane
- Foxytocin receptor activity
- Fvasopressin receptor activity
- Pcell surface receptor signaling pathway
- Pcellular response to hormone stimulus
- Pfemale pregnancy
- PG protein-coupled receptor signaling pathway
- Plactation
- Pmaternal process involved in parturition
- Pmuscle contraction
- Ppositive regulation of cold-induced thermogenesis
- Ppositive regulation of vasoconstriction
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Synaptic signalling
- ·G protein-coupled receptor for oxytocin (OXT), a neuropeptide hormone released by the po…
Ion channel gating
- ·G protein-coupled receptor for oxytocin (OXT), a neuropeptide hormone released by the po…
G protein-coupled signalling
- ·G protein-coupled receptor for oxytocin (OXT), a neuropeptide hormone released by the po…
- ·G protein-coupled receptor signaling pathway
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
4 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene OXTR
Gene-level evidence surfaced through the gene OXTRthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
9 compounds recorded · 4 approved · 5 in clinical development
View all recorded compounds (9)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (10)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- New publicationG Proteins-Associated Dose-Dependent Effects of Oxytocin on Oxytocin Neuronal Activity and Astrocytic Plasticity of the Supraoptic Nucleus.
- New publicationOxytocin and corticotropin-releasing hormone exaggerate nucleus tractus solitarii neuronal and synaptic activity following chronic intermittent hypoxia.
- New publicationConvergence of oxytocin and dopamine signalling in neuronal circuits: Insights into the neurobiology of social interactions across species.
- New publicationSocial anxiety disorder-associated gut microbiota increases social fear.
- New publicationPsychedelics reopen the social reward learning critical period.
- New publicationA randomized controlled trial of intranasal oxytocin in Phelan-McDermid syndrome.
- New publicationOxytocin, Neural Plasticity, and Social Behavior.
- New publicationEffects of single dose intranasal oxytocin on social cognition in schizophrenia.
- New publicationCervical ripening with foley balloon plus fixed versus incremental low-dose oxytocin: a randomized controlled trial.
- New publicationConcurrent dinoprostone and oxytocin for labor induction in term premature rupture of membranes: a randomized controlled trial.
- New publicationA prospective randomized study comparing misoprostol and oxytocin for premature rupture of membranes at term.
- New publicationInduction of labor compared with expectant management for prelabor rupture of the membranes at term. TERMPROM Study Group.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.
Related literature
Papers indexed under “Receptors, Oxytocin” — a subject heading that covers this protein without being specific to it. Shown as context; not counted as this protein's own research activity.
Europe PMC literature, reached through a MeSH descriptor linked to this protein.